Literature DB >> 28248688

Change in Health-related Quality of Life After Referral to Memory Assessment Services.

Min Hae Park1, Sarah C Smith, Theopisti Chrysanthaki, Jenny Neuburger, Craig W Ritchie, A A Jolijn Hendriks, Nick Black.   

Abstract

Despite strong support for the provision of memory assessment services (MASs) in England and other countries, their effectiveness in improving patient outcomes is uncertain. We aimed to describe change in patients' health-related quality of life (HRQL) 6 months after referral to MASs and to examine associations with patient characteristics and use of postdiagnostic interventions. Data from 883 patients referred to 69 MASs and their informal caregivers (n=569) were collected at referral and 6 months later. Multivariable linear regression was used to examine associations of change in HRQL (DEMQOL, DEMQOL-Proxy) with patient characteristics (age, sex, ethnicity, socioeconomic deprivation, and comorbidity) and use of postdiagnostic interventions (antidementia medications and nonpharmacological therapies). Mean HRQL improved, irrespective of diagnosis: self-reported HRQL increased 3.4 points (95% CI, 2.7-4.1) and proxy-reported HRQL 1.3 points (95% CI, 0.5-2.1). HRQL change was not associated with any of the patient characteristics studied. Patients with dementia (54%) receiving antidementia drugs reported greater improvement in their HRQL but those using nonpharmacological therapies reported less improvement compared with those note receiving therapy. HRQL improved in the first 6 months after referral to MASs. Research is needed to determine longer term sustainability of the benefits and the cost-effectiveness of MASs.

Entities:  

Mesh:

Year:  2017        PMID: 28248688     DOI: 10.1097/WAD.0000000000000190

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  4 in total

1.  Characteristics of people with dementia lost to follow-up from a dementia care center.

Authors:  Nicole D Boyd; Georges Naasan; Krista L Harrison; Sarah B Garrett; Talita D'Aguiar Rosa; Brenda Pérez-Cerpa; Shamiel McFarlane; Bruce L Miller; Christine S Ritchie
Journal:  Int J Geriatr Psychiatry       Date:  2021-10-06       Impact factor: 3.485

2.  Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort.

Authors:  Melanie T Gentry; Maria I Lapid; Jeremy Syrjanen; Kendrick Calvert; Samantha Hughes; Danielle Brushaber; Walter Kremers; Jessica Bove; Patrick Brannelly; Giovanni Coppola; Christina Dheel; Bradley Dickerson; Susan Dickinson; Kelley Faber; Julie Fields; Jamie Fong; Tatiana Foroud; Leah Forsberg; Ralitza Gavrilova; Deb Gearhart; Nupur Ghoshal; Jill Goldman; Jonathan Graff-Radford; Neill Graff-Radford; Murray Grossman; Dana Haley; Hilary Heuer; Ging-Yuek Hsiung; Edward Huey; David Irwin; David Jones; Lynne Jones; Kejal Kantarci; Anna Karydas; David Knopman; John Kornak; Joel Kramer; Walter Kukull; Diane Lucente; Codrin Lungu; Ian Mackenzie; Masood Manoochehri; Scott McGinnis; Bruce Miller; Rodney Pearlman; Len Petrucelli; Madeline Potter; Rosa Rademakers; Eliana Marisa Ramos; Katherine Rankin; Katya Rascovsky; Pheth Sengdy; Leslie Shaw; Nadine Tatton; Joanne Taylor; Arthur Toga; John Trojanowski; Sandra Weintraub; Bonnie Wong; Zbigniew Wszolek; Bradley F Boeve; Adam Boxer; Howard Rosen
Journal:  Alzheimers Dement       Date:  2020-07-13       Impact factor: 21.566

3.  Use of the Long-Term Conditions Questionnaire (LTCQ) for monitoring health-related quality of life in people affected by cognitive impairment including dementia: pilot study in UK memory clinic services.

Authors:  Caroline M Potter; Michele Peters; Maureen Cundell; Rupert McShane; Ray Fitzpatrick
Journal:  Qual Life Res       Date:  2021-02-11       Impact factor: 4.147

4.  DEMQOL and DEMQOL-Proxy: a Rasch analysis among those diagnosed with dementia.

Authors:  A A Jolijn Hendriks; Sarah C Smith; Nick Black
Journal:  Health Qual Life Outcomes       Date:  2019-10-26       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.